Department of Medicine, University of Toledo, Toledo, OH 43614, USA.
Am J Ther. 2011 Jan;18(1):e19-21. doi: 10.1097/MJT.0b013e3181c2df83.
Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase (EGFR) inhibitor, which is used for non-small-cell lung cancer treatment. Erlotinib usually has a favorable safety profile however; adverse events such as interstitial lung disease (ILD) have been reported in pivotal studies. ILD usually occurs weeks to months after initiating therapy with Erlotinib. We report a case of Erlotinib induced ILD presenting within 5 days of initiating treatment with Erlotinib.
厄洛替尼是一种人表皮生长因子受体 1/酪氨酸激酶（EGFR）抑制剂，用于治疗非小细胞肺癌。厄洛替尼通常具有良好的安全性，但在关键研究中已报告有间质性肺病（ILD）等不良事件。ILD 通常在开始厄洛替尼治疗后数周至数月发生。我们报告了一例厄洛替尼引起的 ILD 病例，该病例在开始厄洛替尼治疗后 5 天内出现。
